By reshaping both immune and stromal compartments, TGF-β acts as a central driver of tumour progression, making it a possible target for therapeutic strategies aimed at overcoming metastasis and improving immunotherapy efficacy [28,29,30]. This evidence concerns the gene TGFB1 and neoplasm.